The trial's primary end point was the reduction in the number of gadolinium-enhancing lesions.

It suggested that gadolinium chloride could alleviate lung injury, but not prevent lung injury.

Finally, the CHMP recommended that further studies should be carried out on the long-term retention of gadolinium in human tissues.